These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 33465522)
1. Promising anti- cervical carcinoma and inflammatory agent, Resveratrol targets poly (ADP-ribose) polymerase 1 (PARP-1) induced premature ovarian failure with a potent enzymatic modulatory activity. Alharbi H; Alshehri AS; Ahmad M; Guo WW J Reprod Immunol; 2021 Apr; 144():103272. PubMed ID: 33465522 [TBL] [Abstract][Full Text] [Related]
2. Resveratrol inhibits inflammatory signaling implicated in ionizing radiation-induced premature ovarian failure through antagonistic crosstalk between silencing information regulator 1 (SIRT1) and poly(ADP-ribose) polymerase 1 (PARP-1). Said RS; El-Demerdash E; Nada AS; Kamal MM Biochem Pharmacol; 2016 Mar; 103():140-50. PubMed ID: 26827941 [TBL] [Abstract][Full Text] [Related]
3. Development of poly ADP-ribose polymerase-1 inhibitor with anti-cervical carcinoma activity. Zhang TM; Wang W Cell Mol Biol (Noisy-le-grand); 2020 Oct; 66(7):31-34. PubMed ID: 33287919 [TBL] [Abstract][Full Text] [Related]
4. Mechanistic perspective of protective effects of resveratrol against cisplatin-induced ovarian injury in rats: emphasis on anti-inflammatory and anti-apoptotic effects. Said RS; Mantawy EM; El-Demerdash E Naunyn Schmiedebergs Arch Pharmacol; 2019 Oct; 392(10):1225-1238. PubMed ID: 31129703 [TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders. Henning RJ; Bourgeois M; Harbison RD Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072 [TBL] [Abstract][Full Text] [Related]
6. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Bianchi A; Lopez S; Altwerger G; Bellone S; Bonazzoli E; Zammataro L; Manzano A; Manara P; Perrone E; Zeybek B; Han C; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Newberg JY; Pavlick DC; Elvin J; Frampton GM; Schwartz PE; Santin AD Gynecol Oncol; 2019 Oct; 155(1):144-150. PubMed ID: 31434613 [TBL] [Abstract][Full Text] [Related]
7. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors. Zhou Y; Tang S; Chen T; Niu MM Molecules; 2019 Nov; 24(23):. PubMed ID: 31766720 [TBL] [Abstract][Full Text] [Related]
8. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1). Zhang Z; Chang X; Zhang C; Zeng S; Liang M; Ma Z; Wang Z; Huang W; Shen Z J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1606-1615. PubMed ID: 32779949 [TBL] [Abstract][Full Text] [Related]
9. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer. Almahli H; Hadchity E; Jaballah MY; Daher R; Ghabbour HA; Kabil MM; Al-Shakliah NS; Eldehna WM Bioorg Chem; 2018 Apr; 77():443-456. PubMed ID: 29453076 [TBL] [Abstract][Full Text] [Related]
10. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo. Guo C; Zhang F; Wu X; Yu X; Wu X; Shi D; Wang L Int J Biol Macromol; 2020 May; 150():238-245. PubMed ID: 32057845 [TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302 [TBL] [Abstract][Full Text] [Related]
13. Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer. Long H; Hu X; Wang B; Wang Q; Wang R; Liu S; Xiong F; Jiang Z; Zhang XQ; Ye WC; Wang H J Med Chem; 2021 Aug; 64(16):12089-12108. PubMed ID: 34404206 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors. Shen H; Ge Y; Wang J; Li H; Xu Y; Zhu Q Bioorg Med Chem Lett; 2021 Sep; 47():128169. PubMed ID: 34091044 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Lin C; Liu C; Hu P; Zou Z; Sun G Bioorg Chem; 2024 Jul; 148():107455. PubMed ID: 38772289 [TBL] [Abstract][Full Text] [Related]
17. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation. Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983 [TBL] [Abstract][Full Text] [Related]
18. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1 Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y Molecules; 2019 May; 24(10):. PubMed ID: 31108884 [TBL] [Abstract][Full Text] [Related]
19. Carbamoylation at C-8 position of natural 3-arylcoumarin scaffold for the discovery of novel PARP-1 inhibitors with potent anticancer activity. Lu G; Zou Z; Xin M; Meng Y; Cheng Z; Du Z; Gu J; Zhang X; Zou Y Eur J Med Chem; 2024 Nov; 277():116726. PubMed ID: 39116535 [TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors. Xin M; Sun J; Huang W; Tang F; Liu Z; Jin Q; Wang J Future Med Chem; 2020 Oct; 12(19):1691-1707. PubMed ID: 33012191 [No Abstract] [Full Text] [Related] [Next] [New Search]